Discover Six Dynamic Trends to Disrupt the Next Generation of Biopharmaceutical Manufacturing
A rise in new disease outbreaks, the urgency to launch innovative therapies, and new constructs such as multi-valent antibodies are compelling biopharmaceutical companies to adopt new manufacturing approaches.
- A rise in new disease outbreaks, the urgency to launch innovative therapies, and new constructs such as multi-valent antibodies are compelling biopharmaceutical companies to adopt new manufacturing approaches.
- The industry must reduce costs and achieve scalability of downstream processes in global sites to work more efficiently.
- Biopharmaceutical companies must follow suit by adopting advanced manufacturing technologies, establishing public-private partnerships and placing sustainability at the core of the business strategy.\nFrost & Sullivan\'s latest article, Preparing for Next Generation of Biopharmaceutical Manufacturing, analyzes six dynamic trends that will impact the future of biopharmaceutical manufacturing.
- "\nOverall, biopharmaceutical companies need to review investments beyond the traditional growth levers of clinical and commercial excellence and intensify efforts related to sustainability.